Table 2.
Patient and cancer-specific data for patients having selected major COVID-altered management decisions.
| Patients having omitted/incomplete NACT | Patients having ‘Bridging’ ET | Patients undergoing simple Mx when BCS possible | Patients not offered immediate breast reconstruction | Patients not having adjuvant CT | Patients not having adjuvant RT | Patients having five fractions RT | |
|---|---|---|---|---|---|---|---|
| N | 252c | 951c | 42c | 299c | 81c | 96c | 781c |
| Agea | 52 (28–78) | 65 (35–92) | 59 (39–77) | 50 (28–75) | 63 (38–78) | 69 (63–77) | 59 (53–67) |
| Menopausal status (n) | |||||||
| Pre/peri-menopausal | 121 (50) | 154 (18) | 13 (33) | 176 (61) | 20 (25) | 13 (15) | 187 (26) |
| Postmenopausal | 119 (50) | 708 (82) | 27 (67) | 113 (39) | 61 (75) | 76 (85) | 544 (74) |
| Missing | 12 | 89 | 2 | 10 | 0 | 7 | 50 |
| Tumour stage | |||||||
| Is | 0 | 87 (10) | 0 | 23 (8) | 0 | 16 (17) | 46 (6) |
| 1 | 58 (23) | 455 (50) | 15 (37) | 80 (27) | 33 (41) | 57 (61) | 433 (56) |
| 2 | 142 (57) | 310 (34) | 23 (56) | 132 (44) | 39 (49) | 15 (16) | 252 (33) |
| 3 | 40 (16) | 50 (6) | 2 (5) | 58 (20) | 6 (8) | 4 (4) | 40 (5) |
| 4 | 10 (4) | 4 (0) | 1 (2) | 4 (1) | 2 (2) | 2 (2) | 3 (0) |
| Missing | 2 | 45 | 1 | 2 | 1 | 2 | 7 |
| Nodal stage | |||||||
| 0/mi | 125 (50) | 760 (84) | 23 (56) | 175 (59) | 36 (45) | 82 (86) | 638 (83) |
| 1 | 75 (30) | 124 (14) | 14 (34) | 76 (26) | 41 (51) | 12 (13) | 112 (15) |
| 2 | 33 (13) | 10 (1) | 4 (10) | 32 (11) | 3 (4) | 1 (1) | 15 (2) |
| 3 | 17 (7) | 6 (1) | 0 (0) | 14 (5) | 0 (0) | 0 (0) | 6 (1) |
| Missing | 2 | 51 | 1 | 2 | 1 | 1 | 10 |
| Metastases | |||||||
| M0 | 248 (99) | 897 (100) | 41 (100) | 293 (99) | 80 (100) | 95 (100) | 770 (100) |
| M1 | 2 (1) | 3 (0) | 0 (0) | 3 (1) | 0 (0) | 0 (0) | 3 (0) |
| Missing | 2 | 51 | 1 | 3 | 1 | 1 | 8 |
| Size | MMG/USS | MMG/USS | MMG/USS | MMG/USS | Path. | Path. | Path. |
| Size in mmb | 29·0 (1.2) | 20·7 (0.5) | 24·2 (2.2) | 32·8 (1.5) | 27·5 (1.8) | 17·8 (1.4) | 20·3 (0.6) |
| 28·3 (1.0) | 16·9 (0.4) | 23·7 (1.9) | 23·9 (1.0) | ||||
| Missing | 9/8 | 34/39 | 1/1 | 13/9 | 1 | 3 | 20 |
| Histological type | |||||||
| IDC | 226 (92) | 599 (65) | 39 (95) | 207 (71) | 65 (82) | 65 (71) | 548 (72) |
| ILC | 7 (3) | 149 (16) | 0 (0) | 48 (16) | 8 (10) | 5 (5) | 107 (14) |
| Mixed | 4 (2) | 31 (3) | 1 (2) | 9 (3) | 3 (4) | 1 (1) | 26 (3) |
| Other | 9 (4) | 54 (6) | 1 (2) | 6 (2) | 3 (4) | 5 (5) | 40 (5) |
| DCIS | 0 | 94 (10) | 0 | 232 (8) | 0 | 16 (17) | 45 (6) |
| Missing | 6 | 24 | 1 | 6 | 2 | 1 | 15 |
| Grade (invasive) | |||||||
| 1 | 2 (1) | 204 (25) | 1 (2) | 14 (5) | 3 (4) | 19 (26) | 126 (18) |
| 2 | 67 (27) | 507 (62) | 14 (34) | 147 (54) | 42 (53) | 43 (58) | 407 (57) |
| 3 | 178 (72) | 109 (13) | 26 (63) | 110 (41) | 35 (44) | 12 (16) | 181 (25) |
| Missing | 5 | 37 | 1 | 5 | 1 | 3 | 67 |
| Grade (DCIS) | |||||||
| LG | 0 | 12 (14) | 0 | 1 (4) | 0 | 0 (0) | 0 (0.0) |
| IG | 0 | 29 (33) | 0 | 5 (23) | 0 | 4 (27) | 12 (27) |
| HG | 0 | 46 (53) | 0 | 16 (73) | 0 | 11 (73) | 33 (73) |
| Missing | 0 | 7 | 0 | 1 | 0 | 1 | 0 |
| ER | |||||||
| + | 121 (49) | 922 (100) | 24 (59) | 221 (76) | 59 (73) | 76 (89) | 656 (86) |
| − | 127 (51) | 3 (0) | 17 (41) | 71 (24) | 22 (27) | 9 (11) | 104 (14) |
| Missing | 4 | 26 | 1 | 7 | 0 | 8 | 21 |
| PR | |||||||
| + | 78 (33) | 620 (85) | 19 (48) | 160 (63) | 48 (66) | 51 (72) | 462 (71) |
| − | 155 (67) | 106 (15) | 21 (52) | 95 (37) | 25 (34) | 20 (28) | 188 (29) |
| Missing | 19 | 225 | 2 | 44 | 8 | 21 | 221 |
| HER2 | |||||||
| + | 116 (47) | 63 (8) | 8 (20) | 71 (26) | 21 (26) | 3 (4) | 85 (12) |
| − | 132 (53) | 761 (92) | 33 (80) | 205 (74) | 59 (74) | 75 (96) | 636 (88) |
| Missing | 4 | 137 | 1 | 23 | 1 | 15 | 60 |
| Ki67b | 36·2 (3·6) | 18·8 (2·5) | 29·6 (5·1) | 27·4 (3·4) | 24·4 (6·0) | 14.6 (2·5) | 19.8 (1·6) |
| Missing | 213 | 847 | 24 | 246 | 65 | 75 | 654 |
| Comorbidities | |||||||
| None | 6 (2) | 46 (5) | 1 (2) | 6 (2) | 1 (1) | 4 (4) | 19 (2) |
| ≥1 | 246 (98) | 905 (95) | 41 (98) | 293 (98) | 80 (99) | 92 (96) | 762 (98) |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WHO PS | |||||||
| 0 | 197 (79) | 667 (71) | 28 (67) | 261 (87) | 63 (78) | 61 (64) | 658 (85) |
| 1 | 40 (16) | 180 (19) | 9 (21) | 29 (10) | 14 (17) | 26 (27) | 104 (13) |
| 2 | 11 (4) | 74 (8) | 5 (12) | 9 (3) | 4 (5) | 7 (7) | 13 (2) |
| 3 | 2 (1) | 13 (1) | 0 (0) | 0 (0) | 0 (0) | 2 (2) | 2 (0) |
| 4 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Missing | 2 | 17 | 0 | 0 | 0 | 0 | 4 |
NACT neoadjuvant chemotherapy, ET neoadjuvant endocrine therapy, Mx mastectomy, BCS breast-conserving surgery, CT chemotherapy, RT radiotherapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, LG low grade, IG intermediate grade, HG high grade, ER oestrogen receptor, PR progesterone receptor, HER2 Human epidermal growth factor receptor 2, PS performance status.
aMedian (IQR).
bMean (SD).
cPatients could be in more than one category.